Abstract
Rationale: Despite the reported association between OSA and early mortality, RCTs designed to evaluate impact of CPAP on cardiovascular events and all-cause mortality have failed to demonstrate any beneficial effect of therapy.
Methods: This analysis included data from the French health insurance reimbursement database for all new adult initiated on CPAP from January 2015 to December 2016. One year after CPAP initiation, propensity score was applied to define matched populations of patients continuing or stopping CPAP that were then followed for 3 years. Mortality was compared by using Kaplan-Meier curves and comparisons between groups were performed with Log-rank test.
Results: Data from 176 014 patients matched in two groups (88 007 pts) were included (mean age 60 years, 64% male). Compared with CPAP termination, continuation of CPAP was associated with a significantly lower risk of all-cause death (HR: 0.61, 95% CI [0.57–0.65]; Log-rank p<0.01) (Figure A). Cumulative incidence of heart failure and incident hypertension were significantly lower in patients who continued versus terminated CPAP.
Conclusion: this study showed that continued use of CPAP is associated with a reduction in mortality in a large real life cohort of OSA patients. Strategies designed to ensure usage of CPAP in the first year are important and have the potential to contribute to improved overall survival.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA4390.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
